RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus

Arch Med Res. 2009 Jul;40(5):393-8. doi: 10.1016/j.arcmed.2009.06.008.

Abstract

Background and aims: Engagement of the receptor for advanced glycation end products (RAGE) with advanced glycation end products and subsequent signaling play an important role in the development of diabetic complications. This pathophysiological effect was mitigated partially by endogenous secretory RAGE (esRAGE). The present study aimed to explore the possible association of RAGE polymorphism with serum esRAGE level and coronary artery disease (CAD) in Chinese patients with type 2 diabetes mellitus (T2DM).

Methods: A total of 740 consecutive patients with T2DM undergoing coronary angiography were enrolled. The severity of coronary atherosclerosis was defined as the number of diseased vessels; 69 bp insertion/deletion was determined by polymerase chain reactions, and -429 T/C, -374A/T and G82S variants were assessed by polymerase chain reaction-restriction fragment length polymorphism.

Results: Patients with genotypes carrying C allele of -429 T/C and G allele of G82S had significantly higher esRAGE levels. 82S allele was also associated with increased tumor necrosis factor-alpha and interleukin-6 levels in diabetic patients with CAD (all p <0.05), but none of the polymorphisms or haplotypes was related to the presence and severity of CAD.

Conclusions: G82S and -429 T/C polymorphisms of RAGE were associated with the circulating levels of esRAGE but not with CAD in Chinese patients with T2DM.

MeSH terms

  • Aged
  • Alleles
  • C-Reactive Protein / metabolism
  • China
  • Coronary Artery Disease / etiology
  • Coronary Artery Disease / genetics
  • Coronary Artery Disease / metabolism*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / metabolism*
  • Female
  • Genotype
  • Haplotypes / genetics
  • Humans
  • Interleukin-6 / blood
  • Male
  • Middle Aged
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / blood
  • Receptors, Immunologic / genetics*
  • Receptors, Immunologic / metabolism*
  • Tumor Necrosis Factor-alpha / blood

Substances

  • IL6 protein, human
  • Interleukin-6
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein